Literature DB >> 6370429

Treatment of patients with metastatic osteogenic sarcoma: a report from the Children's Cancer Study Group.

E Morgan, E Baum, W A Bleyer, N Movassaghi, A Provisor, B Lampkin, J Lukens, T Griffin, H White, C Fryer.   

Abstract

Fifty-three patients with metastatic osteogenic sarcoma were treated with vincristine, high-dose methotrexate with citrovorum factor rescue, and cisplatin. Metastases were surgically removed in most patients, either prior to chemotherapy or following initial response to therapy. Among 29 previously treated patients, responses to initial chemotherapy included two complete remissions, six partial remissions, and eight patients with stable disease. Twenty-three patients were disease-free, six for greater than 12 months. Toxicity was moderate, but usually reversible. There were two toxic deaths and one unexplained death 48 hours following a dose of cisplatin.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6370429

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN: 0361-5960


  5 in total

Review 1.  Pharmacogenomics of second-line drugs used for treatment of unresponsive or relapsed osteosarcoma patients.

Authors:  Claudia M Hattinger; Serena Vella; Elisa Tavanti; Marilù Fanelli; Piero Picci; Massimo Serra
Journal:  Pharmacogenomics       Date:  2016-11-24       Impact factor: 2.533

2.  Four-drug sequential regimen in advanced breast cancer.

Authors:  L Ferrari; E Bajetta; L Gianni; C Verusio; C Bartoli; P Valagussa; G Bonadonna
Journal:  Breast Cancer Res Treat       Date:  1987-11       Impact factor: 4.872

3.  Axial skeletal osteosarcoma: a 25-year monoinstitutional experience in children and adolescents.

Authors:  Cristina Meazza; Roberto Luksch; Primo Daolio; Marta Podda; Alessandro Luzzati; Alessandro Gronchi; Antonina Parafioriti; Lorenza Gandola; Paola Collini; Andrea Ferrari; Michela Casanova; Monica Terenziani; Filippo Spreafico; Daniela Polastri; Veronica Biassoni; Elisabetta Schiavello; Emilia Pecori; Maura Massimino
Journal:  Med Oncol       Date:  2014-02-21       Impact factor: 3.064

4.  Ifosfamide/etoposide alternating with high-dose methotrexate: evaluation of a chemotherapy regimen for poor-risk osteosarcoma.

Authors:  M P Michelagnoli; I J Lewis; H R Gattamaneni; C C Bailey; L S Lashford
Journal:  Br J Cancer       Date:  1999-03       Impact factor: 7.640

5.  Gemcitabine in bone sarcoma resistant to Doxorubicin-based chemotherapy.

Authors:  O Merimsky; I Meller; Y Kollender; J Issakov; G Flusser; M Inbar
Journal:  Sarcoma       Date:  2000
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.